Press Room

Press Release / Sep 26, 2025

Hovione honored with the Leonardo da Vinci Prize 2025

Presented by the Hénokiens Association and the Château du Clos Lucé

Leonardo da Vinci Prize | Hovione

Lisbon, Portugal, 25 September 2025 – Hovione, a Portuguese-founded multinational and family-owned business specialized in the development and manufacturing of pharmaceutical products, has received the Leonardo da Vinci Prize 2025, awarded by the Hénokiens Association and the Château du Clos Lucé. In its 14th edition, the prize was presented in Lisbon to Ms. Diane Villax, founder and member of the Board of Directors of Hovione, by former Portuguese Deputy Prime Minister Paulo Portas, before an audience of global business leaders and public figures.

“This award recognizes Hovione’s commitment to science, innovation and service to patients worldwide. It reflects the values that have guided us from the start – honesty, integrity, scientific rigor and teamwork – with a long-term vision that puts people and progress at the center. Above all, it is a tribute to the people of Hovione, whose passion and dedication ensure we remain, in every sense, In it for life,” said Diane Villax, Founder and member of the Board of Directors of Hovione.

“This recognition strengthens our resolve to build for the future, drawing on our heritage, culture, and the passion of our employees as we expand our global reach to partners and patients. We remain dedicated to advancing innovation, deepening partnerships with the pharmaceutical industry, and ultimately helping deliver better medicines to improve lives,” said Dr. Jean-Luc Herbeaux, CEO of Hovione.

Founded in 1959, Hovione remains a family-owned company, employing 2,400 people across five manufacturing facilities (Loures and Seixal - Portugal; New Jersey - US; Cork - Ireland; and Macau), two R&D centers, and eight regional offices worldwide. With a strong scientific foundation, the company supports the pharmaceutical industry in addressing its most complex challenges and has contributed to 29 new drugs approved by the US FDA in the last decade, representing in some years as much as 10% of the total, improving the lives of an estimated 80 million patients every year.

Hovione has played a decisive role in some of the world’s greatest public health breakthroughs - from manufacturing ivermectin, the Nobel Prize-winning treatment for river blindness, to producing three of the four hepatitis C drugs that have cured over 4 million patients, and enabling the world’s first COVID-19 approved treatment, Veklury®, which reached 6.5 million patients. Beyond science, the company has shown a strong commitment to society, from donating nearly 1 million bottles of sanitizing gel during the pandemic, to investing in education through supporting Nova University school of Sciences and Technologies, the significant financial contribution to NOVA School of Business and Economics, among other, and recently becoming the new official sponsor of the Portuguese National Rugby Team, including support for youth talent development.

 

About Hovione
Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices. Hovione's culture is based on innovation, quality and dependability. Hovione is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.

About Henokiens Association
The International Henokiens Association, created in France in 1981, brings together bicentennial family businesses from around the world. Descendants of the founders are still the owners or majority stakeholders of the 57 member companies, based in 10 countries. Through its members and the values they embody, the association aims to promote the concept of the family business as an alternative to multinationals. www.henokiens.com

About Château du Clos Lucé
Château du Clos Lucé - Parc Leonardo da Vinci, located in Amboise, is the residence where Leonardo da Vinci settled in 1516 at the invitation of King Francis I. Appointed “First Painter, Engineer and Architect to the King”, he worked tirelessly on numerous projects before passing away 500 years ago. The Saint Bris family has owned the property since 1855, and opened this cultural landmark to the public almost one hundred years later, in 1954. The family’s mission is to pass on the universal heritage, memory and knowledge of Leonardo da Vinci’s work to as many people as possible. In 2019, the Château du Clos Lucé welcomed 520,000 visitors, 25% of whom were from abroad. It is the 3rd most visited monument in the Loire Valley. Thanks to digital technologies, Clos Lucé is continuing its digital transformation and in June 2021 inaugurated the Leonardo da Vinci Painter and Architect Galleries, a new 500 square metre cultural facility. Visitors are immersed in the creative process and the entire painted work of the Renaissance genius in an immersive audiovisual show. www.vinci-closluce.com/en

 

 

Also in the Press Room

See All

The latest from CDMOs, CMOs, and suppliers featuring Thermo Fisher Scientific, Lonza, SK pharmteco/Lotte Biologics, Hovione, Sai Life Sciences, BioCina, Alcami, Piramal Pharma/IntoCell and Roquette. Formulation Development/Drug Product Manufacturing: Hovione Completes Initial $100-M Investment Cycle in US Operations Hovione, a CDMO of drug substances and drug products, has completed an initial $100-million investment cycle at its site in East Windsor, New Jersey, as part of a strategy to increase its US operations and enhance its integrated drug-substance, drug-product intermediate, and drug-product capabilities. Upon completion, the site will cover more than 200,000 square feet.   The initial expansion phase includes a 31,000-square-foot building that will house two size-3 spray dryers (PSD-3) designed for production of amorphous solid dispersions (ASDs). This investment more than doubles Hovione’s spray-drying capacity in the US by expanding capabilities for ASD development and commercial manufacturing. Construction is underway at the New Jersey site, with GMP operations planned to start in the second quarter of 2026.  As part of this expansion, Hovione has also acquired additional adjacent land to enable future growth at the East Windsor site. The 125,000-square-foot greenfield will support large-scale production, including continuous and batch tableting capacity, and introduce the latest pharmaceutical technologies and digital innovation with enhanced quality control and R&D capabilities.    Read the full article at DCATvci.org  

Press Clipping

Supplier News: Thermo Fisher, Lonza, SK pharmteco, Hovione & More

Oct 30, 2025

Today marks the start of CPhI Frankfurt, a huge trade show in Germany focused on the supply of pharmaceutical ingredients and other services to the drug industry. C&EN editor in chief Nick Perkins, life sciences editor Laura Howes, and reporter Aayushi Pratap are all there to meet drug outsourcing executives and take the pulse of the sector. In advance of CPhI, Cambrex and Wilmington PharmaTech both just announced big investments in US plants that make active pharmaceutical ingredients. And the Portuguese pharmaceutical services firm Hovione says it has completed a $100 million investment in New Jersey (story below). (...) Hovione invests in spray-drying in New Jersey The pharmaceutical services firm Hovione says it has spent $100 million to expand its operation in East Windsor, New Jersey. The facility spray-dries drug ingredients to create amorphous solid dispersions, which improve solubility and bioavailability. The Portuguese company says the new spray dryers will begin operating in the second quarter of 2026. The New Jersey facility opened in 2002, making Hovione one of the longest-established European pharmaceutical services firms in the US, CEO Jean-Luc Herbeaux says in a press release. Hovione says it has purchased land adjacent to the East Windsor site on which it can add new facilities for services such as spray-drying and drug tableting. Hovione is also investing at its sites in Ireland and Portugal. —Michael McCoy   Read the full article at CEN.acs.org  

Press Clipping

Oct. 28 Business Watch: More plants closing in Europe, Novartis to pay $12 billion for biotech firm

Oct 28, 2025

Developing drugs with poor water solubility remains a major challenge for pharmaceutical manufacturers, because solubility impacts bioavailability and effective drug delivery. The vast majority of small molecule drug candidates have low water solubility. For more than two decades, the most successful particle engineering technology to improve drug solubility and bioavailability has been spray drying with an amorphous solid dispersion (ASD) platform. Spray drying improves the solubility of oral drugs, inhalable particles, and excipients, and increases the stability of heat-sensitive drug products. Hovione, recognized globally for its industry-leading spray drying capabilities, has recently completed a $100 million investment cycle to enhance its operations in New Jersey. This initiative has successfully doubled Hovione’s spray-drying capacity in the US, strengthening its position in the industry. Hovione’s Expanded U.S. Site in East Windsor, NJ  The first phase of the expansion in East Windsor, NJ, delivers a new 31,000 square foot facility and houses two size-3 spray dryers (PSD-3). This additional capacity allows Hovione to meet increasing customer demand for ASD development and good manufacturing practice (GMP) commercial production. GMP operations are scheduled to commence in the second quarter of 2026.  Hovione has also acquired 15 acres of neighboring land, strategically positioning itself for future growth and evolving customer needs for U.S. manufacturing. The newly acquired greenfield site will provide future support for PSD-4–scale commercial production as well as continuous and batch tableting production. It will also be a hub for centralized logistics, enhanced quality control laboratories, and next-generation research and development facilities.  A Global CDMO with a Growing U.S. Footprint  Hovione has operated in New Jersey for more than two decades, establishing itself with a strong U.S. presence for the production of drug substances, intermediates, and finished drug products. A continued emphasis on an integrated service offering, including spray drying, supports delivering innovative medicines to patients more quickly.  The expansion of the East Windsor site addresses the rising demand for U.S. manufacturing and is an integral part of the company's ongoing global growth strategy, with facilities in Portugal, Ireland, and Macau. The company continues to bolster a cohesive network for drug development and commercial manufacturing unified by a corporate quality system and governance framework.  The integrated offering enhances development speed and eases technology transfers by unifying the team's technical skills, proprietary technologies, and digital platforms to efficiently produce drug substance to drug products at a single-site, through Hovione’s “one site, one partner” vision. Furthermore, Hovione’s strategic partnership model offers customers exclusive access to advanced technologies and resources while aiding in the optimization of their development programs and ensuring sustained value creation.  End-to-End Spray Drying and Particle Engineering: From Grams to Tons Hovione is a global leader in spray drying and particle engineering. Services include solubility enhancement and controlled-modified release via development and production of ASDs of both small and large molecules, supporting various modalities. ASD-HIPROS, Hovione’s proprietary spray drying screening platform, identifies optimal formulations that offer optimal performance and stability. By increasing production volume in the US, Hovione will meet customer demand for spray drying services:  Development services in the laboratory (1 g – 1 kg batches)  Pilot scale production (0.5 – 25 kg batches)  Small-scale production (5 – 200 kg batches)  Large-scale commercial manufacturing (50 – 400 kg batches) A Commitment to Sustainability  Hovione’s core values include a commitment to sustainability at all facilities. This commitment is reflected in a business strategy that focuses on improving the communities where the company operates. Hovione’s sustainability policy and strategy align with the UN Sustainable Development Goals and include adherence to science-based targets in line with the Paris Agreement to address climate change. Meeting these goals has required a dedication to process intensification and ensuring sustainability of manufacturing processes. This has been possible through strategic planning and commitments from senior management to ensure sustainability is addressed throughout the drug development life cycle.  Partner with a Technology-Leading CDMO for U.S. Manufacturing   As demand for poorly water-soluble drug formulations continues to rise in the U.S., expanding spray drying throughput is essential to meet the need for innovative therapeutics. With proven leadership in spray drying to manufacture ASDs, Hovione is able to support pharmaceutical companies by solving their solubility challenges efficiently and reliably.  Partnering with a CDMO that combines global leadership, advanced technologies, and the necessary manufacturing capacity in the U.S., drug developers can expedite time to market, ensure quality, and deliver innovative medicines to patients faster.  If your company is seeking access to the latest spray-drying capabilities, expanded U.S. manufacturing capacity, and an accelerated path to regulatory filing and commercialization, contact our team today.     

News

Hovione is Expanding Spray Drying Capacity for U.S. Drug Manufacturing

Oct 27, 2025